ORGANIZATION

19 Companies Join JPMA Task Force on Quality Evaluation of Nucleic Acid Therapeutics

September 18, 2018
Nineteen companies have joined the Japan Pharmaceutical Manufacturers Association’s (JPMA) task force on the quality evaluation of nucleic acid therapeutics. The task force, which was set up this spring, includes first and second-tier companies, both Japanese and foreign companies, indicating…

To read the full story

ORGANIZATION

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…